-
Something wrong with this record ?
Mitochondrial Probe Methyltriphenylphosphonium (TPMP) Inhibits the Krebs Cycle Enzyme 2-Oxoglutarate Dehydrogenase
M. Elkalaf, P. Tůma, M. Weiszenstein, J. Polák, J. Trnka,
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Cell Line MeSH
- Citric Acid Cycle drug effects MeSH
- Citrate (si)-Synthase drug effects metabolism MeSH
- Glutamate Dehydrogenase drug effects metabolism MeSH
- Isocitrate Dehydrogenase drug effects metabolism MeSH
- Ketoglutarate Dehydrogenase Complex antagonists & inhibitors metabolism MeSH
- Muscle, Skeletal enzymology MeSH
- Rats MeSH
- Malate Dehydrogenase drug effects metabolism MeSH
- Membrane Potential, Mitochondrial drug effects MeSH
- Onium Compounds pharmacology MeSH
- Rats, Wistar MeSH
- Pyruvate Dehydrogenase Complex drug effects metabolism MeSH
- Mitochondria, Muscle drug effects enzymology MeSH
- Triphenylmethyl Compounds pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Methyltriphenylphosphonium (TPMP) salts have been widely used to measure the mitochondrial membrane potential and the triphenylphosphonium (TPP+) moiety has been attached to many bioactive compounds including antioxidants to target them into mitochondria thanks to their high affinity to accumulate in the mitochondrial matrix. The adverse effects of these compounds on cellular metabolism have been insufficiently studied and are still poorly understood. Micromolar concentrations of TPMP cause a progressive inhibition of cellular respiration in adherent cells without a marked effect on mitochondrial coupling. In permeabilized cells the inhibition was limited to NADH-linked respiration. We found a mixed inhibition of the Krebs cycle enzyme 2-oxoglutarate dehydrogenase complex (OGDHC) with an estimated IC50 3.93 [3.70-4.17] mM, which is pharmacologically plausible since it corresponds to micromolar extracellular concentrations. Increasing the lipophilic character of the used TPP+ compound further potentiates the inhibition of OGDHC activity. This effect of TPMP on the Krebs cycle ought to be taken into account when interpreting observations on cells and mitochondria in the presence of TPP+ derivatives. Compounds based on or similar to TPP+ derivatives may also be used to alter OGDHC activity for experimental or therapeutic purposes.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031501
- 003
- CZ-PrNML
- 005
- 20171025123027.0
- 007
- ta
- 008
- 171025s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0161413 $2 doi
- 035 __
- $a (PubMed)27537184
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Elkalaf, Moustafa $u Laboratory for Metabolism and Bioenergetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Centre for Research on Diabetes, Metabolism and Nutrition, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Mitochondrial Probe Methyltriphenylphosphonium (TPMP) Inhibits the Krebs Cycle Enzyme 2-Oxoglutarate Dehydrogenase / $c M. Elkalaf, P. Tůma, M. Weiszenstein, J. Polák, J. Trnka,
- 520 9_
- $a Methyltriphenylphosphonium (TPMP) salts have been widely used to measure the mitochondrial membrane potential and the triphenylphosphonium (TPP+) moiety has been attached to many bioactive compounds including antioxidants to target them into mitochondria thanks to their high affinity to accumulate in the mitochondrial matrix. The adverse effects of these compounds on cellular metabolism have been insufficiently studied and are still poorly understood. Micromolar concentrations of TPMP cause a progressive inhibition of cellular respiration in adherent cells without a marked effect on mitochondrial coupling. In permeabilized cells the inhibition was limited to NADH-linked respiration. We found a mixed inhibition of the Krebs cycle enzyme 2-oxoglutarate dehydrogenase complex (OGDHC) with an estimated IC50 3.93 [3.70-4.17] mM, which is pharmacologically plausible since it corresponds to micromolar extracellular concentrations. Increasing the lipophilic character of the used TPP+ compound further potentiates the inhibition of OGDHC activity. This effect of TPMP on the Krebs cycle ought to be taken into account when interpreting observations on cells and mitochondria in the presence of TPP+ derivatives. Compounds based on or similar to TPP+ derivatives may also be used to alter OGDHC activity for experimental or therapeutic purposes.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a citrátsynthasa $x účinky léků $x metabolismus $7 D002950
- 650 _2
- $a citrátový cyklus $x účinky léků $7 D002952
- 650 _2
- $a glutamátdehydrogenasa $x účinky léků $x metabolismus $7 D005969
- 650 _2
- $a isocitrátdehydrogenasa $x účinky léků $x metabolismus $7 D007521
- 650 _2
- $a ketoglutarátdehydrogenasový komplex $x antagonisté a inhibitory $x metabolismus $7 D007655
- 650 _2
- $a malátdehydrogenasa $x účinky léků $x metabolismus $7 D008291
- 650 _2
- $a membránový potenciál mitochondrií $x účinky léků $7 D053078
- 650 _2
- $a svalové mitochondrie $x účinky léků $x enzymologie $7 D008931
- 650 _2
- $a kosterní svaly $x enzymologie $7 D018482
- 650 _2
- $a oniové sloučeniny $x farmakologie $7 D009861
- 650 _2
- $a pyruvátdehydrogenasový komplex $x účinky léků $x metabolismus $7 D011768
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a tritylové sloučeniny $x farmakologie $7 D014320
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tůma, Petr $u Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Centre for Research on Diabetes, Metabolism and Nutrition, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Weiszenstein, Martin $u Department of Sport Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Centre for Research on Diabetes, Metabolism and Nutrition, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Polák, Jan $u Department of Sport Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Centre for Research on Diabetes, Metabolism and Nutrition, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Trnka, Jan $u Laboratory for Metabolism and Bioenergetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Centre for Research on Diabetes, Metabolism and Nutrition, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 8 (2016), s. e0161413
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27537184 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025123109 $b ABA008
- 999 __
- $a ok $b bmc $g 1255094 $s 992528
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 11 $c 8 $d e0161413 $e 20160818 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20171025